Alpha-9 Oncology

Edit info

Founded: 2018

Location: Boston, MA

Employee range: 11 - 50

Clinical stage: Clin1

Therapy area: Prostate cancer

Drug types: ONC

Lead product: A9-3202

Funding: $75M B Dec 2022; $11M A Apr 2021

Investors: Nextech Invest, Frazier Life Sciences, Samsara BioCapital, Quark Venture, Longitude Capital, BVF Partners

a9oncology.com

linkedin.com

job board

Drug notes:

5+ additional undisclosed programs RD/Clin0 multiple cancers, undisclosed

About:

Alpha-9 Theranostics is a clinical stage company developing highly selective, peptide-based radiopharmaceuticals for cancer treatment. Their treatments are developed with a binder, linker, chelator, and radioisotope, giving them high selectivity for delivering radiation to cancer cells with minimal off-target effects. Their developed molecules are optimized for imaging, dosimetry, and therapy studies to evaluate the tumor uptake and dose delivery, as well as determine the optimal patient population. Alpha-9 Theranostics was founded in 2019 by researchers in British Columbia to improve the lives of people with metastatic cancers. Alpha-9 Theranostics’ new research facility in Vancouver was completed in 2023, housing chemistry, biology, and radiochemistry R&D teams to accelerate their discovery efforts.